The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...
– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...
Advancing a once-annual preventive RNAi medicine designed to reduce the two key drivers of cardiovascular disease: LDL-C and blood pressure Filed application for COR-1004, a novel siRNA targeting ...
STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...
A new national programme that aims to position Singapore at the forefront of advancements in RNA science and applications was officially launched today. This new initiative – named National Initiative ...
Nicholas Dreisbach (left) is a Senior Associate Scientist in the RNA team at ElevateBio (MA, USA), where he deploys his skills as an expert in capillary gel electrophoresis (CGE) technologies. His ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results